Startups
Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.
Ironwood Pharmaceuticals will split into two independent companies, Ironwood and what is currently being dubbed R&D Co.
Proniras Corporation launched from Accelerator Life Science Partners to treat nerve agents. The company recently received a contract from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) for $89.5 million.
Mammoth Biosciences, based in San Francisco, has officially launched to develop CRISPR technology for clinical diagnostics.
With $37 million in its pocket a new player has emerged to develop treatments for rare diseases.
Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.
Urovant Sciences has been busy the past few weeks. In March the company initiated a Phase III trial for an overactive bladder treatment, strengthened its management team and established a U.S. headquarters in Irvine, California.
One month after filing for bankruptcy anti-obesity company Orexigen Therapeutics, Inc. could be acquired by the newly-formed company Nalpropion Pharmaceuticals, Inc. for $75 million in cash.
About two years ago, former president and chief executive officer of Sarepta Therapeutics, Chris Garabedian, formed Xontogeny, a biotech accelerator. Xontogeny was founded to support life science technology startups.
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
PRESS RELEASES